# Acorn Bioventures

> Acorn Bioventures is a VC fund backing Biotechnology and Health Care. See 32 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 32
- Last investment: Mar 2026
- Lead investor: 19%
- Fund size: $200M
- Last fund: Mar 2019
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/acorn-bioventures/
- Website: http://www.acornbioventures.com

Acorn Bioventures is a VC fund in New York focused on Biotechnology and Health Care. Our invest in and partner with private and small capitalization biotech, specialty pharma and medical device companies.

## Contacts

5 contacts available for Acorn Bioventures. Shizune tracks 2 team members at Acorn Bioventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/acorn-bioventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 18 | 56% |
| Health Care | 16 | 50% |
| Therapeutics | 13 | 41% |
| Biopharma | 7 | 22% |
| Medical | 6 | 19% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 13 | 41% |
| Series B | 6 | 19% |
| Series C | 3 | 9% |
| Series A | 2 | 6% |
| Funding Round | 2 | 6% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 17 | 53% |
| United Kingdom | 2 | 6% |
| Canada | 1 | 3% |
| Ireland | 1 | 3% |
| Switzerland | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Anders Hove | Partner & Founder | 15 | https://shizune.co/investors/profile/anders-hove |
| Isaac Manke | Partner | 8 | https://shizune.co/investors/profile/isaac-manke |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| OnKure Therapeutics | OnKure is a biotechnology company that commercializes a new cancer therapy based on novel, less toxic kinase inhibitor drugs. The company is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that includes selective inhibitors of histone deacetylases. In pre-clinical models of both hematological and solidtumor cancers, their lead candidate, OKI-179, significantly and safely reduces the growth rate of tumors when dosed by itself or in combination with other targeted therapies.OnKure advances the HDAC3 selective inhibitor OKI-422 into pre-clinical toxicology studies. The company's drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized. | $150M | Post-IPO Equity | Mar 27, 2026 |  |
| Cybin | Cybin is a biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin's mission is to revolutionize mental healthcare. | $175M | Post-IPO Equity | Oct 28, 2025 |  |
| Neuron23 | Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease. | $96.5M | Series D | Jun 24, 2025 |  |
| OnKure Therapeutics | OnKure is a biotechnology company that commercializes a new cancer therapy based on novel, less toxic kinase inhibitor drugs. The company is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that includes selective inhibitors of histone deacetylases. In pre-clinical models of both hematological and solidtumor cancers, their lead candidate, OKI-179, significantly and safely reduces the growth rate of tumors when dosed by itself or in combination with other targeted therapies.OnKure advances the HDAC3 selective inhibitor OKI-422 into pre-clinical toxicology studies. The company's drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized. | $65M | Post-IPO Equity | Oct 04, 2024 |  |
| Acrivon Therapeutics | Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success. They specifically apply its approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single-gene driver mutations or synthetic lethalcontexts. The company aims to rapidly progress in-licensed clinical-stage assets and a pipeline of internally developed programs through accelerated registration trials. | $130M | Post-IPO Equity | Apr 09, 2024 |  |
| Protara Therapeutics | Protara Therapeutics develops transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy created for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipidsubstrate replacement therapy for the treatment of intestinal failure-associated liver disease.The Protara team prioritizes creativity, diverse perspectives, and tenacity to expedite their goal of bringing life-changing therapies to people with limited treatment options. | $45M | Post-IPO Equity | Apr 05, 2024 |  |
| Neurosterix | Neurosterix aims to create novel medicines based on allosteric modulation that overcome the limitations of traditional treatments and have the potential to significantly enhance patients' lives. | $65M | Series A | Apr 03, 2024 |  |
| Q32 Bio | Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.Q32 Bio consists of ateam of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies. | $42M |  | Mar 25, 2024 |  |
| Q32 Bio | Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.Q32 Bio consists of ateam of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies. | $42M | Post-IPO Equity | Mar 25, 2024 |  |
| Cybin | Cybin is a biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin's mission is to revolutionize mental healthcare. | $150M | Post-IPO Equity | Mar 13, 2024 |  |

10 of 32 investments shown.

## Co-investors
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 10 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 10 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 9 deals together
- [Surveyor Capital](https://shizune.co/investors/profile/surveyor-capital) — VC Fund, 9 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 7 deals together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 5 deals together

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

### Similar country
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund
- [NDRC](https://shizune.co/investors/profile/ndrc) — VC Fund
- [Act Venture Capital](https://shizune.co/investors/profile/act-venture-capital) — VC Fund

## Featured in investor lists
- [Health Care Investors in Ireland](https://shizune.co/investors/health-care-investors-ireland)
- [Health Care VC Funds in Ireland](https://shizune.co/investors/health-care-vc-funds-ireland)

## FAQ

### What does Acorn Bioventures invest in?

Acorn Bioventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Series B stage. Most of the 32 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Acorn Bioventures?

Public channels for Acorn Bioventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Acorn Bioventures?

The team at Acorn Bioventures includes Anders Hove (Partner & Founder) and Isaac Manke (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co